{"id":"induction-chemotherapy-mdcf","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":{"chemblId":"CHEMBL1201419","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"mDCF (modified docetaxel, cisplatin, and fluorouracil) is a triplet chemotherapy combination where docetaxel acts as a microtubule stabilizer, cisplatin causes DNA cross-linking, and fluorouracil inhibits thymidylate synthase. Together, these agents target rapidly dividing cancer cells through multiple mechanisms to achieve cytotoxic effects in advanced digestive tract malignancies.","oneSentence":"mDCF is a combination chemotherapy regimen that uses docetaxel, cisplatin, and fluorouracil to inhibit cancer cell division and induce apoptosis in gastric and esophageal cancers.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:54.931Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic or locally advanced gastric cancer (induction therapy)"},{"name":"Esophageal cancer (induction therapy)"}]},"trialDetails":[{"nctId":"NCT06207981","phase":"PHASE3","title":"Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2024-02-26","conditions":"Anal Cancer","enrollment":310}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"induction chemotherapy (mDCF)","genericName":"induction chemotherapy (mDCF)","companyName":"Federation Francophone de Cancerologie Digestive","companyId":"federation-francophone-de-cancerologie-digestive","modality":"Small molecule","firstApprovalDate":"","aiSummary":"mDCF is a combination chemotherapy regimen that uses docetaxel, cisplatin, and fluorouracil to inhibit cancer cell division and induce apoptosis in gastric and esophageal cancers. Used for Metastatic or locally advanced gastric cancer (induction therapy), Esophageal cancer (induction therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}